Small Molecule Cohort
Therapeutic Science
Becomes Investable.
The Small Molecule Cohort supports CEOs advancing
therapeutic programs from discovery and validation toward
clinical and capital readiness.
Many companies possess strong science but struggle translating technical progress into investor confidence and executable development plans.
CEO360 helps CEOs build small molecule companies investors trust.
CEO360 Small Molecule Cohort
The Small Molecule
Cohort Serves
Companies Developing:
- Novel therapeutic programs
- Pre-clinical or early clinical assets
- Small molecule platforms or pipelines
- Seed to Series A stage
- Venture-backed or venture-seeking CEOs
Small Molecule
Company Categories
Small Molecule
Oncology Therapeutics
CNS & Neurological
Rare Disease Therapeutics
Immunology & Inflammation
Metabolic & Endocrine
Infectious
Disease
Targeted Small Molecule
AI-Enabled Drug Discovery
Small Molecule
Common Challenges
CEOs In Small Molecule Face:
- Translating science into executable development plans
- IND and regulatory readiness uncertainty
- Capital strategy misalignment
- Execution discipline under investor scrutiny
- Manufacturing readiness planning
Small Molecule
2026 Sprint Calendar
CEOs progress through Four Execution Sprints:
-
Sprint #1 - Take Control April, 2026Leadership & company clarity
-
Sprint #2 - Build a Moat July, 2026Defensibility & regulatory realism
-
Sprint #3 - Capital Justification October, 2026Capital & milestone logic
-
Sprint #4 - Make It Scalable December, 2026Scale & strategic readiness
What CEOs Can
Accomplish In 4 Sprints
By the end of the program, CEOs typically achieve:
- Clear development and regulatory pathways
- Milestones aligned with capital strategy
- Stronger investor narrative grounded in execution discipline
- Reduced diligence risk across science and execution
- Leadership and governance readiness for capital
- Investor relationships built through demonstrated progress
- Companies leave positioned for productive investor engagement.
Small Molecule
Cohort Partners
